Gossamer Bio (GOSS) Payables (2018 - 2026)

Gossamer Bio has reported Payables for 9 years, with the latest figure at $6.0 million in Q2 2026.

• On a quarterly basis, Payables rose 217.22% year-over-year to $6.0 million in Q2 2026; TTM through Jun 2026 was $6.0 million, a 217.22% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 156.96% from the prior year.
• Payables was $6.0 million for Q2 2026 at Gossamer Bio, down from $10.8 million in the prior quarter.
• The five-year high for Payables was $10.8 million in Q1 2026, with the low at $363000.0 in Q3 2022.
• Average Payables over 5 years is $3.1 million, with a median of $2.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Payables slumped 69.37% in 2022, then soared 361.32% in 2023.
• Over 5 years, Payables stood at $1.5 million in 2022, then jumped by 278.75% to $5.5 million in 2023, then plunged by 58.03% to $2.3 million in 2024, then soared by 156.96% to $6.0 million in 2025, then declined by 0.13% to $6.0 million in 2026.
• The last three Payables figures came in at $6.0 million (Q2 2026), $10.8 million (Q1 2026), and $6.0 million (Q4 2025), per Business Quant data.